-
AACR18 Recap: Immunotherapy in the Spotlight
Immunotherapy took center stage and dominated the headlines at AACR18.
-
AACR18 Update: Lloyd J. Old Award, Overcoming Immunotherapy Resistance, and the Importance of Dendritic Cells
Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and…
-
AACR18 Day 3 Update: Lung Cancer in the Spotlight, Immune Memory, and New Immunotherapy Biomarkers
Day 3 of AACR18 highlighted potentially “practice-changing” immunotherapy breakthroughs in lung cancer, and insights into the factors…
-
Checkpoint Immunotherapy Combination Approved for First-line Treatment of Advanced Kidney Cancer
The combination of checkpoint immunotherapies against PD-1 and CTLA-4 significantly improved survival and response rates compared to…
-
AACR18: Driving Innovative Cancer Science to Patient Care
This year’s annual AACR meeting boasts an impressive lineup of presentations highlighting both clinical and preclinical immunotherapy…
-
Healthcare Experts Tackle Tough Challenges at Fortune Brainstorm HEALTH 2018
CRI CEO highlights next steps in immunotherapy’s advancement at Fortune’s premier healthcare conference
-
Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only…
-
Recap of the Fourth Annual Immuno-Oncology 360° Conference
The Fourth Annual Immuno-Oncology 360° Conference focused on comprehensive strategies for advancing immunotherapy, and was held from February…
-
Immuno-Oncology 360°: Taking Immunotherapy to the Next Level
By bringing together diverse stakeholders, IO360 hopes to facilitate the collaborations that will advance immunotherapy.
